Paper
0
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation
Authors
Richard Stone,Sumithra Mandrekar
Ben Sanford,Kristina Laumann,Susan Geyer,Clara Bloomfield,Christian Thiede,Thomas Prior,Konstanze Döhner,Guido Marcucci,Francesco Lo‐Coco,Rebecca Klisovic,Andrew Wei,Jorge Sierra,Miguel Sanz,Joseph Brandwein,Théo Witte,Dietger Niederwieser,Frederick Appelbaum,Bruno Medeiros,Martin Tallman,Jürgen Krauter,Richard Schlenk,Arnold Ganser,Hubert Serve,Gerhard Ehninger,Sergio Amadori,Richard Larson
+26 authors
,Hartmut DöhnerPublished
Jun 23, 2017
Show more
Save
Tip0
TipSave
Abstract
Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation — to standard chemotherapy would prolong overall survival in this population.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.